Navigation Links
Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
Date:5/12/2010

Acquisition Extends Consulting and Implementation Capabilities and Software Offerings of Xybion Corporation

(PRWEB) May 12, 2010 -- Xybion Corporation announced today that it has completed the acquisition of substantially all of the operating assets of Stelex and Vital-Path from GE Healthcare. The terms of the transactions were not disclosed.

Stelex and Vital-Path, based in Bensalem, PA is a strategic addition to Xybion’s enterprise software and consulting solutions focus for the life sciences, finance, manufacturing and other regulated industries. Stelex and Vital-Path provide a range of products and services to regulated industries such as:

- Asset and Facilities Management solutions including services and support for IBM’s Maximo, a leading software solution that enables the user to develop comprehensive programs for preventive, predictive, routine and unplanned maintenance for assets and facilities

- Enterprise Content Management and Migration solutions to assist clients in taking control of their mission critical content and to seamlessly share data among disparate departmental content repositories

- Regulatory Compliance solutions and System integration and implementation services for regulated industries.

The acquisition will extend Xybion’s software, consulting and Implementation capabilities and increase the company’s enterprise client base.

“The addition of Stelex and Vital-Path will advance Xybion’s vision of being the enterprise system partner of choice for life sciences product companies and CROs worldwide,” said Dr. Pradip K. Banerjee, Chairman and CEO of Xybion Corporation. “Stelex’s solutions, talent and customers enhance Xybion’s business and extend our ability to deliver compelling products and services to enterprise customers. Stelex’s reputation in quality assurance and validation consulting for the pharmaceutical and life science industry is unparalleled. In addition, their experience and positioning with partners like IBM and OpenText complement Xybion’s expansion into other markets with a focus on business process and quality management improvements in both regulated and non-regulated industries."

“This is an exciting milestone for our company, and we look forward to scaling our growth as part of Xybion,” said Tony Kashani, president of Stelex. “Xybion’s global reach, widely recognized brand and customer relationships make an ideal fit for Stelex. Like Xybion, we have our roots in the life sciences and have expanded our opportunities with offerings in other markets. Our combined teams will create exciting growth opportunities for both of our customers and our employees. We look forward to working with the Xybion team to ensure a rapid and seamless transition.”

Stelex’s Bensalem, PA office will function as Xybion’s Center of Excellence for the Xybion consulting and Implementation business. The acquisition more than doubles Xybion’s size and adds significant staff capabilities in development, sales and marketing for Xybion. Xybion currently has offices in the United States, Canada, and Europe.

About Xybion
Xybion is the enterprise system partner of choice for life sciences product companies and research organizations worldwide for end-to-end needs in the pre-clinical R&D, Quality, and Regulatory risk and compliance management solutions. In addition to Pristima™, Pristima™ VM, Providence, eQRP, and eQCM, Xybion also provides professional services, consulting, training and validation activities to clients around the world. Learn more about Xybion at xybion.com.

About Stelex
For over twenty years, Stelex has provided solutions and services to improve business processes for regulated and non-regulated industries, by providing the expertise, strategies and technology to help clients mitigate risk, enhance productivity and increase profitability. Stelex is a client-centered organization, tailoring solutions to address the specific requests and needs of clients. Stelex assists clients in meeting requirements and achieving their business goals. Learn more about Stelex at stelex.com.

###

Read the full story at http://www.prweb.com/releases/Xybion/Stelex/prweb3983884.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management
2. Korea Institute of Toxicology Implementing Xybion's Pristima™
3. Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
4. Hendrick Construction Completes Oak Ridge National Laboratory Expansion
5. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
6. Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S.
7. NOVAVAX Completes Enrollment of Pivotal H1N1 Influenza Vaccine Clinical Trial in Mexico
8. EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
9. APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
10. Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial
11. Neuralstem Completes $5.25 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016 This market research report on the ... prospects of the market in terms of revenue (USD ... in the manufacture of microbiology culture media and related ... market snapshot providing the overall information of various market ... section also provides the overall information and data analysis ...
(Date:2/9/2016)... , February 9, 2016 Three-Year ... Enables Children to Take Part in Life-Changing Camp ... new initiative designed to positively affect the lives of children born ... care. --> SHPG ) is announcing a new initiative ... diseases, as well as the future of rare disease care. ...
(Date:2/9/2016)... , Feb. 9, 2016 ... Inhibitors-Pipeline Insights, 2016", report provides in depth ... development activities around the Protein-Tyrosine Phosphatase 1B ... product profiles in various stages of development ... II, Phase III and Preregistration. Report covers ...
(Date:2/8/2016)... 2016 Should antibiotic bone cement products be ... prevent infection after standard total hip or knee replacement ... Institute have been fielding a lot lately. ... Line?" --> "Antibiotic Bone Cement: ... --> While there isn,t a simple answer, ...
Breaking Biology Technology:
(Date:2/8/2016)... Czech Republic , February 8, 2016 /PRNewswire/ ... EU-regulated global payment platform which presents innovation for ... Biometrics Authentication feature called VoiceKey. --> ... platform which presents innovation for clients, comfort and ... called VoiceKey. --> Worldcore ...
(Date:2/3/2016)... Sweden , February 4, 2016 --> ... amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter ... profit amounted to SEK 517.6 M (loss: 30.0). Earnings per ... operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
Breaking Biology News(10 mins):